Literature DB >> 7494409

Treatment of cystic fibrosis based on understanding CFTR.

A E Smith1.   

Abstract

In the five years since the gene associated with cystic fibrosis was isolated, rapid progress has been made in understanding the structure and function of CFTR, the gene product. Based on the knowledge that CFTR is a cAMP-regulated chloride channel in the apical surface of epithelia in many tissues, new approaches to treating CF disease have emerged. These include development of agents to open alternative chloride channels, to relocate mutant CFTR, which commonly is mislocalized because of a trafficking defect, and to deliver CFTR using protein or gene therapy. Although the underlying basis of each of these approaches is now well understood, major practical problems face each of them. Nevertheless, it is difficult not to be optimistic that new therapies will emerge.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494409     DOI: 10.1007/bf00710062

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  22 in total

1.  Systemic gene expression after intravenous DNA delivery into adult mice.

Authors:  N Zhu; D Liggitt; Y Liu; R Debs
Journal:  Science       Date:  1993-07-09       Impact factor: 47.728

2.  Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats.

Authors:  J Zabner; D M Petersen; A P Puga; S M Graham; L A Couture; L D Keyes; M J Lukason; J A St George; R J Gregory; A E Smith
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

3.  Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor.

Authors:  T Ferkol; C S Kaetzel; P B Davis
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.

Authors:  M R Knowles; N L Church; W E Waltner; J R Yankaskas; P Gilligan; M King; L J Edwards; R W Helms; R C Boucher
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

Review 5.  The basic science of gene therapy.

Authors:  R C Mulligan
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

6.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations.

Authors:  J H Felgner; R Kumar; C N Sridhar; C J Wheeler; Y J Tsai; R Border; P Ramsey; M Martin; P L Felgner
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

7.  Role of early region 3 (E3) in pathogenesis of adenovirus disease.

Authors:  H S Ginsberg; U Lundholm-Beauchamp; R L Horswood; B Pernis; W S Wold; R M Chanock; G A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.

Authors:  T R Flotte; S A Afione; C Conrad; S A McGrath; R Solow; H Oka; P L Zeitlin; W B Guggino; B J Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

9.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

10.  Correction of cAMP-stimulated fluid secretion in cystic fibrosis airway epithelia: efficiency of adenovirus-mediated gene transfer in vitro.

Authors:  J Zabner; L A Couture; A E Smith; M J Welsh
Journal:  Hum Gene Ther       Date:  1994-05       Impact factor: 5.695

View more
  2 in total

Review 1.  Cystic fibrosis: five years beyond the gene.

Authors:  D J Porteous
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

2.  Mechanisms of lipid malabsorption in Cystic Fibrosis: the impact of essential fatty acids deficiency.

Authors:  N Peretti; V Marcil; E Drouin; E Levy
Journal:  Nutr Metab (Lond)       Date:  2005-05-03       Impact factor: 4.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.